CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 140 filers reported holding CLOVIS ONCOLOGY INC in Q1 2016. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $2,421,000 | +309.6% | 82,430 | +534.1% | 5.78% | +350.9% |
| Q2 2018 | $591,000 | -13.8% | 13,000 | 0.0% | 1.28% | -4.7% |
| Q1 2018 | $686,000 | -32.7% | 13,000 | -13.3% | 1.34% | +52.5% |
| Q4 2017 | $1,020,000 | -17.5% | 15,000 | 0.0% | 0.88% | -20.5% |
| Q3 2017 | $1,236,000 | -12.0% | 15,000 | 0.0% | 1.11% | -13.8% |
| Q2 2017 | $1,404,000 | -26.5% | 15,000 | -50.0% | 1.29% | -9.3% |
| Q1 2017 | $1,910,000 | +43.3% | 30,000 | 0.0% | 1.42% | +33.5% |
| Q4 2016 | $1,333,000 | -7.4% | 30,000 | -60.0% | 1.06% | -4.6% |
| Q1 2016 | $1,440,000 | -17.7% | 75,000 | +50.0% | 1.11% | -3.7% |
| Q4 2015 | $1,750,000 | -67.5% | 50,000 | -14.6% | 1.16% | -61.1% |
| Q3 2015 | $5,386,000 | +17.0% | 58,567 | +11.8% | 2.97% | -18.5% |
| Q2 2015 | $4,605,000 | +10.8% | 52,400 | -6.4% | 3.65% | +4.7% |
| Q1 2015 | $4,156,000 | +174.9% | 55,988 | +107.4% | 3.48% | +132.8% |
| Q4 2014 | $1,512,000 | – | 27,000 | – | 1.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |